Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA209997,10.1016/j.ccell.2023.10.006,Cancer Cell,37922910,https://pubmed.ncbi.nlm.nih.gov/37922910,Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer,2023,"Immunotherapy, Clinical Trial, Tumor Microenvironment, Metastatic Prostate Cancer, Adt, Clinical Translational Science, Hormone-sensitive, Anti-pd-1 Therapy, Single Cell Rna Sequencing","Jessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, Emerson A Lim, Karie Runcie, Casey R Ager, James McKiernan, Christopher B Anderson, Guarionex J Decastro, Joshua Weintraub, Renu Virk, Israel Lowy, Jianhua Hu, Matthew G Chaimowitz, Xinzheng V Guo, Ya Zhang, Michael C Haffner, Jeremy Worley, Mark N Stein, Andrea Califano, Charles G Drake","When compared to other malignancies, the tumor microenvironment (TME) of primary and castration-resistant prostate cancer (CRPC) is relatively devoid of immune infiltrates. While androgen deprivation therapy (ADT) induces a complex immune infiltrate in localized prostate cancer, the composition of the TME in metastatic castration-sensitive prostate cancer (mCSPC), and the effects of ADT and other (Read more on Pubmed)","Clinical Study, Single Cell RNA-Sequencing, Quantitative Multiplex Immunofluorescence       ",Prostate Neoplasm,Prostate Gland,10.17632/5nnw8xrh5m.1,Open Access,37922910,32907daa-ef1c-4dda-9bd7-3264331d81d3,syn52500280
